Comazole is contraindicated in patients with marked liver parenchymal damage. It is also contraindicated in patients with severe renal insufficiency when repeated determinations of the plasma concentration cannot be made.
Except in rare circumstances Comazole should not be given to patient with serious haematological disorders. The combination has occasionally been administered to patients receiving cytotoxic agents for the treatment of leukemias, without evidence of any adverse effect on the bone marrow or peripheral blood.
Comazole should not be administered to patients with a history of hypersensitivity to sulphonamides or trimethoprim.
For safety reasons Comazole is contraindicated during pregnancy. If pregnancy cannot be excluded, possible risks should be balanced against the expected therapeutic effect.
Comazole should not be given to premature and newborn infants during the first week of life.
Comazole is contraindicated in G6PD (Glucose-6-phosphate dehydrogenase deficiency). Treatment must be immediately discontinued on the appearance of a skin rash or any element of blood count reduced.